MenB Research Articles

Group B Meningococcal Disease on Campus Again

In the U.S., Neisseria meningitidis serogroup B (MenB) is responsible for about half of all cases of invasive meningococcal disease in people aged 17 to 22. Recently, two MenB vaccines were licensed for use in this country. On February 2, 2015, a case of MenB disease was reported in a male student attending Providence College. Three days later, …

A Potential Vaccine for the Group B Meningococcus

Serogroup B Neisseria meningitidis (menB) is a major cause of nonepidemic meningococcal disease in industrialized countries. Although an effective vaccine against meningococci of serogroups A, C, Y, and W-135 was developed in the 1970s, the similarity between the capsular polysaccharide of menB and …